Skip to Main Content

Paper Details

2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.
Circ Cardiovasc Qual Outcomes
3
2017
Sildenafil
Adolescent, Age Factors, Child, Child, Preschool, Drug Approval, Drug Development, Government Regulation, Health Policy, Humans, Hypertension, Pulmonary, Infant, Patient Safety, Pediatrics, Phosphodiesterase 5 Inhibitors, Policy Making, Risk Assessment, Risk Factors, Sildenafil Citrate, Treatment Outcome, United States, United States Food and Drug Administration, Vasodilator Agents
Author NameAffiliation
Craig SableAmerican College of Cardiology Representative. American Heart Association Representative. American Academy of Pediatrics Representative. US Food and Drug Administration Representative. Retired from the US Food and Drug Administration during the development of this statement.
Dunbar IvyAmerican College of Cardiology Representative. American Heart Association Representative. American Academy of Pediatrics Representative. US Food and Drug Administration Representative. Retired from the US Food and Drug Administration during the development of this statement.
Robert H BeekmanAmerican College of Cardiology Representative. American Heart Association Representative. American Academy of Pediatrics Representative. US Food and Drug Administration Representative. Retired from the US Food and Drug Administration during the development of this statement.
Helene D Clayton-JeterAmerican College of Cardiology Representative. American Heart Association Representative. American Academy of Pediatrics Representative. US Food and Drug Administration Representative. Retired from the US Food and Drug Administration during the development of this statement.
Kathy J JenkinsAmerican College of Cardiology Representative. American Heart Association Representative. American Academy of Pediatrics Representative. US Food and Drug Administration Representative. Retired from the US Food and Drug Administration during the development of this statement.
William T MahleAmerican College of Cardiology Representative. American Heart Association Representative. American Academy of Pediatrics Representative. US Food and Drug Administration Representative. Retired from the US Food and Drug Administration during the development of this statement.
William R MorrowAmerican College of Cardiology Representative. American Heart Association Representative. American Academy of Pediatrics Representative. US Food and Drug Administration Representative. Retired from the US Food and Drug Administration during the development of this statement.
Dianne MurphyAmerican College of Cardiology Representative. American Heart Association Representative. American Academy of Pediatrics Representative. US Food and Drug Administration Representative. Retired from the US Food and Drug Administration during the development of this statement.
Robert M NelsonAmerican College of Cardiology Representative. American Heart Association Representative. American Academy of Pediatrics Representative. US Food and Drug Administration Representative. Retired from the US Food and Drug Administration during the development of this statement.
Geoffrey L RosenthalAmerican College of Cardiology Representative. American Heart Association Representative. American Academy of Pediatrics Representative. US Food and Drug Administration Representative. Retired from the US Food and Drug Administration during the development of this statement.
Norman StockbridgeAmerican College of Cardiology Representative. American Heart Association Representative. American Academy of Pediatrics Representative. US Food and Drug Administration Representative. Retired from the US Food and Drug Administration during the development of this statement.
David L WesselAmerican College of Cardiology Representative. American Heart Association Representative. American Academy of Pediatrics Representative. US Food and Drug Administration Representative. Retired from the US Food and Drug Administration during the development of this statement.
  • 1 - 12

Datasets